Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Doxilar-OD
- Development stage
- Unknown
- Lead developer
- Mercury Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Doxilar-OD** is an oral fixed-dose antiemetic and prenatal vitamin combination marketed by Mercury Laboratories for nausea and vomiting during pregnancy. Each tablet contains doxylamine 20 mg, pyridoxine 20 mg, and folic acid 5 mg. Doxylamine is a first-generation histamine H1-receptor antihistamine that suppresses histamine-mediated and vestibular inputs involved in nausea and vomiting; pyridoxine supports vitamin B6 status and has antiemetic utility in pregnancy, while folic acid provides prenatal folate supplementation. ([apollopharmacy.in](https://www.apollopharmacy.in/medicine/doxilar-od-tablet-10-s))
- Brand names
- Doxilar-OD
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Doxilar-OD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Doxilar-OD.